Sweat-test based non-invasive diagnosis for lung cancer
A wearable skin patch sensor device captures sweat VOCs to non-invasively diagnose lung cancer, addressing the limitations of current screening methods by providing early detection and continuous monitoring of therapeutic efficacy.
Patent Information
- Application Number
- PCT/US2026/027296
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2025-05-08
- Filing Date
- 2026-05-08
- Publication Date
- 2026-11-12
AI Technical Summary
Current lung cancer screening methods are invasive, costly, and lack non-invasive tools for early detection and differentiation between early and metastatic stages, particularly in high-risk ethnic groups, with existing tests being patient non-compliant and ineffective in reducing mortality.
A wearable skin patch sensor device that captures volatile organic compounds from sweat using a sensor strip with a coated microfiber or membrane, connected to a colorimetric reader, to diagnose lung cancer non-invasively and differentiate between early and metastatic stages by detecting aldehydes as biomarkers.
Enables non-invasive, cost-effective, and patient-friendly lung cancer screening, allowing for early detection and continuous monitoring of therapeutic efficacy through wearable technology, reducing healthcare burden and improving patient compliance.
Smart Images

Figure IMGF000001_0001 
Figure IMGF000011_0001_TABLE 
Figure IMGF000012_0001_TABLE
Abstract
Description
[0001] SWEAT-TEST BASED NON-INVASIVE DIAGNOSIS FOR LUNG CANCER
[0002] Cross-Reference to Related
[0003]
[0004] This international patent application claims benefit of priority under 35 U.S.C §119(e) of provisional application U.S. Serial No. 63 / 802,508, filed May 8, 2025, the entirety of which is hereby incorporated by reference.
[0005] BACKGROUND OF THE INVENTION
[0006] Field of the Invention
[0007] The present invention relates generally to the fields of wearable technology and cancer diagnosis. More specifically, the present invention relates to a diagnostic screening kit including a wearable skin patch sensor device configured for chemo-selective capture of compounds from diffused sweat for early cancer detection.
[0008] Description of the Related Art
[0009] According to the American Lung Association, lung cancer has the highest mortality among all cancers. The National Cancer Institute reports that 55% of lung cancers are metastatic with a 5-year relative survival of just 7%. In 2022, there were 236,740 new cases of lung cancer in the US and 130,180 lung cancer-associated deaths. This is likely because currently recommended screening tests for lung cancer are costly and least patient compliant. Lung cancer screening is key to early diagnosis, and early diagnosis saves lives. For example, in 2022, only 5.8% of those eligible were screened.
[0010] The major problem is the current limitations in screening for lung cancer. According to the CDC, the only currently recommended screening test for lung cancer is low dose computed tomography (CT) scanning which requires visit to the clinical facility, chest scanning using a radiolabeled tracer. To many patients the test is costly thereby making it least patient compliant (1). The Cochrane Review suggests limited effectiveness of lung cancer screeningwith chest radiography (CXR) or sputum cytology in reducing lung cancer-related mortality. In addition, the alternative low-dose CT screening failed to reduce lung cancer-related mortality.
[0011] To date, no screening test is available that can non-invasively detect cancer, particularly lung cancer, in sweat. Other than analyzing the lung biopsy samples, currently there is no kit available that can differentiate metastatic lung cancer from an early-stage cancer. As metastatic lung cancer patients have a higher prevalence in a wide range of ethnic groups (Blacks (76.1), Whites (69.7), American Indians / Alaska Natives (48.4), and Asian / Pacific Islanders (38.4) all per 100K.
[0012] Thus, there is a need in the art for diagnostic tools configured to noninvasively screen for lung cancers early, differentiate between the early and metastatic stages of lung cancer in human subjects, do not require visits to a clinical facility, easy to diagnose, cost-effective, and more patient compliant to significantly increase a patient’s therapeutic outcome. Particularly, the art is deficient in a wearable diagnostic skin patch configured to colorimetrically detect volatile organic compounds (VOCs) as lung cancer biomarkers. The present invention fulfills this long standing need and desire in the art.
[0013] SUMMARY OF THE INVENTION
[0014] The present invention is directed to a device to collect a bodily fluid from a subject as a diagnostic of a lung cancer. The device has a sensor strip and means to immobilize the sensor strip within the device.
[0015] The present invention also is directed to a kit to detect a lung cancer in a subject. The kit has the sensor strip as described herein and a colorimetric reader in electronic contact with the sensor strip.
[0016] The present invention is further directed to a method for detecting volatile organic compounds in sweat from a subject in need thereof. In the method a patch comprising the sensor strip as described herein is placed on the subject such that the sensor strip interfaces with the skin and passive sweat from the subject is absorbed therein. The volatile organic compound are captured by the coated microfiber or the coated membrane and a colorimetric signal is measured with the colorimetric reader, where the signal correlates to a presence of the VOC compound in the sweat. The present invention is directed to a related method further comprising diagnosing a lung cancer in the subject as a metastatic lung cancer based on the presence of the volatile organic compounds.The present invention is directed further still to a method for treating a metastatic lung cancer in a subject. In the method a therapeutically effective amount of a Janus Kinase 3-targeted drug is administered to the subject.
[0017] The present invention is directed further still to a system to detect aldehydes in passive sweat as biomarkers of a lung cancer in a subject. The system has a wearable patch with a sensor strip that is a coated microfiber or coated membrane immobilized in a microchip and a colorimetric reader in electronic connection with the microchip.
[0018] Other and further aspects, features, and advantages of the present invention will be apparent from the following description of the presently preferred embodiments of the invention. These embodiments are given for the purpose of disclosure.
[0019] BRIEF DESCRIPTION OF THE DRAWINGS
[0020] So that the matter in which the above-recited features, advantages and objects of the invention, as well as others which will become clear, are attained and can be understood in detail, more particular descriptions of the invention briefly summarized above may be had by reference to certain embodiments thereof which are illustrated in the appended drawings. These drawings form a part of the specification. It is to be noted, however, that the appended drawings illustrate preferred embodiments of the invention and therefore are not to be considered limiting in their scope.
[0021] FIG. 1 is a schematic diagram showing Jak3 overexpression led to increased volatile organic compounds formation.
[0022] FIG. 2 is a schematic design for the sweat-test device aldehyde reactions.
[0023] FIG. 3 illustrates the design for the skin-patch for the detection of lung cancer.
[0024] FIGS. 4A-4P show the skin patch detection, respectively, of standard aldehyde samples glutaraldehyde, 4-hydroxynonenal, hexanal, nonanal, octanal, formaldehyde, MDA salt, and decanal. Left panels (FIGS. 4A, 4C, 4E, 4G, 4I, 4K, 4M, and 40) shows the differences in color intensity and differentiating peak patterns among the standard aldehyde samples.
[0025] FIGS. 5A-5G show color quantification or mean intensity of standard aldehydes at different sweat volume at different stages of detection.
[0026] FIGS. 6A-6B show the skin patch detection system optimized for a sweat volume of 0.02 pL (FIG. 6A) and 5.0 pL (FIG. 6B).
[0027] FIG. 7 compares Jak3 overexpression in different cancers.FIGS. 8A-8M show the high and low expression levels over time of STAT1, STAT2, STAT3, STAT4, STAT5A, STAT5B, and STAT6 (FIGS. 8A-8G), JAK1 , JAK2 and JAK3 (FIGS.
[0028] 8H-8J), TYK2 (FIG. 8K), SRC (FIG. 8L), and FYN (FIG. 8M) in lung cancer.
[0029] FIGS. 9A-9J show the skin-patch detection of lung cancer using sweat samples from Control (FIG. 9A) or two separate lung cancer patients (FIGS. 9C and 9E and FIGS. 9G and 89I). Right panels in the Control (FIG. 9B), each detected skin-patch (FIGS. 9D and 9H) or dip-strip (FIG. 9F and 9J) shows the differences in color intensity (N) and differentiating peak patterns compared to the controls.
[0030] DETAILED DESCRIPTION OF THE INVENTION
[0031] As used herein, the term “a” or “an” when used in conjunction with the term “comprising” in the claims and / or the specification may mean “one,” but it is also consistent with the meaning of “one or more,” “at least one,” and “one or more than one.” Some embodiments of the invention may consist of or consist essentially of one or more elements, method steps, and / or methods of the invention. It is contemplated that any method described herein can be implemented with respect to any other method described herein.
[0032] As used herein, the term “or” in the claims is used to mean “and / or” unless explicitly indicated to refer to alternatives only or the alternatives are mutually exclusive, although the disclosure supports a definition that refers to only alternatives and “and / or.”
[0033] As used herein, the terms "comprise" and "comprising" are used in the inclusive, open sense, meaning that additional elements may be included.
[0034] As used herein, the terms "consist of" and "consisting of" are used in the exclusive, closed sense, meaning that additional elements may not be included.
[0035] As used herein, the term “about” refers to a numeric value, including, for example, whole numbers, fractions, and percentages, whether or not explicitly indicated. The term “about” generally refers to a range of numerical values (e.g., ± 5-10% of the recited value) that one of ordinary skill in the art would consider equivalent to the recited value (e.g., having the same function or result). In some instances, the term “about” may include numerical values that are rounded to the nearest significant figure.
[0036] As used herein, the conditional language, such as, among others, “can”, “might”, “may”, “e.g.”, “for example”, and the like, unless specifically stated otherwise, or otherwise understood within the context as used, is generally intended to convey that certain embodiments include, while other embodiments do not include, certain features, elements and / or states. Thus, such conditional language is not generally intended to imply thatfeatures, elements and / or states are in any way required for one or more embodiments or that one or more embodiments necessarily include logic for deciding, with or without author input or prompting, whether these features, elements and / or states are included or are to be performed in any particular embodiment.
[0037] As used herein, the term “subject” and “patient” refer to any person that is a recipient of the non-invasive sweat-based diagnostic test.
[0038] In one embodiment of the present invention there is provided a device to collect a bodily fluid from a subject as a diagnostic of a lung cancer, comprising a sensor strip; and means to immobilize the sensor strip within the device.
[0039] In this embodiment the sensor strip may comprise a plurality of layers configured to chemically select and colorimetrically identify volatile organic compounds present in the bodily fluid. Particularly, the volatile organic compound is an aldehyde. Also the means to immobilize the sensor strip may be a coated microfiber or a coated membrane in a microchip, the microchip in electronic connection with a colorimetric reader. In one aspect, the coated microfiber or the coated membrane may comprise a coating of quaternary ammonium aminooxy reagent / metalloporphyrins (ATM), polyethyleneimine (PEI) or 2,4-dinitrophenylhydrasine (DNPH) or a combination thereof. In another aspect the coated microfiber or the coated membrane may be a cellulose acetate (CA) membrane or a polytetrafluoroethylene (PTFE) membrane. In addition the lung cancer may be a metastatic lung cancer.
[0040] Also in this embodiment the plurality of layers may comprise an absorbent layer selective for the bodily fluid; a signal transduction layer configured to convert a volatile organic compound detected in the bodily fluid into a perceivable color change; a reagent coated capture layer configured to capture the volatile organic compound; and a microporous sweat-permeable layer. Further to this embodiment the plurality of layers may comprise an adhesive layer to secure the device to the subject.
[0041] In one aspect of this embodiment, the device may be a wearable patch removably attachable to the skin. In this aspect, the bodily fluid may be sweat. In another aspect the device may be a dip-strip. In this aspect, the bodily fluid may be urine or serum.
[0042] In another embodiment of the present invention, there is provided a kit to detect a lung cancer in a subject, comprising the sensor strip as described supra; and a colorimetric reader in electronic contact with the sensor strip.
[0043] In yet another embodiment of the present invention, there is provided a method for detecting volatile organic compounds in sweat from a subject in need thereof, comprising placing a patch comprising the sensor strip of the kit as described supra on the subject such that the sensor strip interfaces with the skin; absorbing therein passive sweat from the subject;capturing the volatile organic compounds by the coated microfiber or the coated membrane; and measuring a colorimetric signal with the colorimetric reader, the signal correlating to a presence of the volatile organic compound in the sweat. Further to this embodiment the method comprises diagnosing a lung cancer in the subject as a metastatic lung cancer based on the presence of the volatile organic compounds. In both embodiments the volatile organic compounds are biomarkers for a metastatic lung cancer.
[0044] In yet another embodiment of the present invention there is provided a method for treating a metastatic lung cancer in a subject, comprising: administering to the subject a therapeutically effective amount of a Janus Kinase 3-targeted drug.
[0045] In yet another embodiment of the present invention there is provided a system to detect aldehydes in passive sweat as biomarkers of a lung cancer in a subject, comprising a wearable patch with a sensor strip that is a coated microfiber or a coated membrane immobilized in a microchip; and a colorimetric reader in electronic connection with the microchip.
[0046] In this embodiment the coated microfiber or the coated membrane comprises a quaternary ammonium aminooxy reagent / metalloporphyrins (ATM), polyethyleneimine (PEI) or 2,4-dinitrophenylhydrasine (DNPH) or a combination thereof. Also in this embodiment, the coated microfiber or the coated membrane may be made of cellulose acetate or polytetrafluoroethylene (PTFE). Particularly, the coated microfiber or the coated membrane comprises an adhesive layer to interface with the skin; an absorbent layer selective for the passive sweat; a signal transduction layer configured to convert the aldehyde detected in the passive sweat into a perceivable color change; a reagent coated capture layer configured to capture the aldehyde; and a microporous sweat-permeable layer. In addition, in this embodiment the lung cancer may be a metastatic lung cancer.
[0047] The present invention provides a kit with a wearable / skin patch sensor device with a sensor strip and colorimetric reader. The sensor strip comprises an immobilized chemical coated microfiber or chemical coated membrane embedded in a microchip for chemo selective capture of volatile organic compounds and connected to the colorimetric pad containing aniline-based ink with a capability of changing color upon contact with volatile organic compounds. The membrane may be, but is not limited to, a cellulose acetate membrane or a polytetrafluoroethylene membrane. The coated microfiber or coated membrane may comprise a coating of quaternary ammonium aminooxy reagent / metalloporphyrins, polyethyleneimine or 2,4-dinitrophenylhydrasine or a combination thereof.
[0048] During diagnosis, this entire wearable or skin patch device is placed on the skin such that the sensor strip interfaces firmly with the skin through selectively permeable barrier to absorb low volumes of sweat. Alternatively, the wearable / skin patch may be structured in adip-strip format to detect volatile organic compounds in other bodily fluids, for example, urine or serum. This avoids any skin sensitivity issues from sticking the skin patch to the skin.
[0049] The present invention provides a method for detecting the volatile organic compounds from diffused or passive sweat are captured by chemical coated microfiber in microchip and a corresponding appearance of the colorimetric signal. A calibration curve developed by measuring the colorimetric response from control, non-metastatic, and metastatic cancer patients can differentiate between the normal, early stage and metastatic lung cancer. This enables the diagnostic skin patch to provide Jak3 and STAT3 as non-invasive drug targeted in lung cancer by detecting aldehydes, such as, but not limited to, hexanal, nonanal, 4-HNE, and / or MDA. The aldehydes are lung cancer volatile organic compound biomarkers due to Jak3-STAT3-dominated pro-inflammatory, oxidative tumor microenvironment in lung cancer (or any other cancer that overexpresses Jak3) as a target and enables real time monitoring of the therapeutic success of a Jak3-targeted cancer drug.
[0050] Additionally, methods are provided for treating a metastatic lung cancer upon detection of the volatile organic compounds in the subject or patient in need thereof. Treatment may be effected by administering a therapeutic targeting Janus Kinase3 (Jak3) or STAT3. Such therapeutics are known in the art. One of ordinary skill in the art is well-able to determine dosage and dosage regimen for the patient.
[0051] The diagnostic skin patch is able to noninvasively detect and differentiate early stage and metastatic stage of lung-cancer through testing for a specific volatile organic compound profile in the sweat of human patients. Thus, this skin patch-based detection enables lung cancer screening by making it noninvasive, continuous, and accessible. Advantages of the skin patch to detect lung cancer and to monitor post-diagnosis therapeutic efficacy of Jak3 or STAT3 targeted drugs include:
[0052] 1. Noninvasive and patient-friendly: Unlike biopsies or even repeated imaging like CT scan, a skin patch avoids needles, radiation, and hospital visits. This makes it far more acceptable for routine screening.
[0053] 2. Continuous or longitudinal monitoring: Awearable patch can collect data overtime (hours to days), rather than giving a single snapshot like blood tests or imaging. This is valuable because cancer-related biomarkers such as volatile organic compounds or inflammatory signals can fluctuate.
[0054] 3. Early detection potential: If designed to detect subtle biochemical changes (e.g., metabolites, cytokines, or tumor-derived exosomes), patches could identify disease earlier than symptom-driven diagnosis. Early detection is critical in lung cancer, where survival strongly depends on its stage at diagnosis.4. Point-of-care and at-home use: Skin patches may enable decentralized diagnostics, patients can use them at home without specialized equipment. This reduces dependence on hospitals and improves access in underserved areas.
[0055] 5. Cost-effectiveness (long-term): Once scaled, wearable biosensors are cheaper than repeated imaging or invasive diagnostics, especially for high-risk populations, e.g., smokers.
[0056] 6. Integration with digital health systems: Patches may be paired with smartphones or cloud platforms for real-time data analysis, alerts, and remote physician monitoring in alignment with precision medical / diagnostic trends.
[0057] 7. Reduced healthcare burden: By filtering out low-risk individuals and flagging high-risk ones early, such tools may reduce unnecessary imaging and invasive procedures.
[0058] The following examples are given for the purpose of illustrating various embodiments of the invention and are not meant to limit the present invention in any fashion.
[0059] EXAMPLE 1
[0060] Materials and methods
[0061] Real-time electrochemical detection of aldehydes
[0062] The real-time electrochemical detection of aldehydes uses coated electrodes (DNPH or amine-based as used in the skin-patch) followed by protocol for cyclic voltammetry (CV) and chronoamperometry (CA) and integrating this system into a wearable electronics platform.
[0063] Setup Materials:
[0064] Electrode system: Screen-printed electrode (carbon or gold), DNPH-coated;
[0065] Electrochemical workstation: Lab: CHI Instruments, PalmSens, Autolab; Wearable: LMP91000 + ESP32;
[0066] Electrolyte: Phosphate-buffered saline (PBS, pH 6.5-7.4) or synthetic sweat;
[0067] Aldehyde standards: Formaldehyde, acetaldehyde, malondialdehyde (MDA).
[0068] Cyclic Voltammetry (CV) protocol to characterize redox behavior and aldehyde response.
[0069] Parameters:
[0070] Working electrode: DNPH- or PEI-coated SPE;
[0071] Counter electrode: Ag / AgCI;
[0072] Potential range: -0.2 V to +9.8 V vs Ag / AgCI;
[0073] Scan rate: 50-100 mV / s;
[0074] Sweeps: 2-3 cycles per concentration.Procedure:
[0075] 1. Immense electrode in PBS or synthetic sweat;
[0076] 2. Add standard aldehyde, e.g., 10 pM formaldehyde) to solution;
[0077] 3. Run CV scan from -0.2 V to +0.8 V;
[0078] 4. Identify oxidation peak -+0.4 to +0.6 V (depends on aldehyde type and coating); and
[0079] 5. Repeat with higher concentrations (10 pM to 500 pM) to generate calibration curve.
[0080] Chronoamperometry (CA) protocol for real-time quantification and wearable integration:
[0081] Parameters:
[0082] Potential: Fixed at aldehyde oxidation peak, e.g., +0.5 V vs Ag / AgCI;
[0083] Duration: 120-300 seconds;
[0084] Sampling rate: 1 Hz or higher; and
[0085] Analyte additions: Spike small aliquots of aldehyde standard.
[0086] Procedure:
[0087] 1. Hold potential constant at +0.5;
[0088] 2. Record baseline for 60 seconds;
[0089] 3. Add aldehyde, e.g., 10 pM formaldehyde;
[0090] 4. Monitor current response-sharp rise followed by plateau;
[0091] 5. Repeat for increasing concentration; and
[0092] 6. Plot current (pA) vs concentration to determine sensitivity and LOD.
[0093] Typical Signal:
[0094] Formaldehyde: 0.2-1.5 pA per 10 pM with DNPH-modified electrodes;
[0095] Linear range: 10-500 pM; and
[0096] LOD: ~1-5 pM depending on coating and system.
[0097] Integration with Wearable Electronics
[0098] Hardware Stack:
[0099] Electrochemical front end: Tl LMP91000 AFE, configurable for amperometry / CV;
[0100] Microcontroller: ESP32 or Arduino Nano 33 BLE - Bluetooth + low power + analog I / O;
[0101] Power supply: 3.7V LiPo battery + boost converter - for -3.3V operation;BLE communication: Built-in or via HM-10 module - T ransmit real-time data to mobile app; and
[0102] Mobile App: MIT App Inventor / Flutter- Graphical display of aldehyde levels.
[0103] App Interface options:
[0104] Real-time current plot (like an ECG display);
[0105] Color-coded indicator, e.g., green < 50 pM; red > 100 pM aldehydes;
[0106] Data export (CSV / email for research use); and
[0107] Geo-stamp or time-stamp logs.
[0108] Integration notes:
[0109] Shield electronics with PDMS or parylene from sweat;
[0110] Place sensor in a hydrophilic microfluidic patch with flow control; and Include temperature and pH sensors to normalize aldehyde response (sweat rate dependent).
[0111] Testing the skin patch for VOC detection
[0112] The procedure to test the skin patch for ability to detect VOC aldehydes per the following steps:
[0113] 1. Allow sweat samples to be absorbed on the skin patch;
[0114] 2. Dry the membrane for 10 min;
[0115] 3. Dip the membrane quickly for second in EDTA solution;
[0116] 4. Dry the membrane for 1 min;
[0117] 5. Add 10 pl color developer;
[0118] 6. Wait for 1-5 min (red to purple color develops after reacting with VOCs); and 7. Add 10 pl H2O2 solution color stabilized and turns pink to red.
[0119] Color quantification of standard aldehydes at different sweat volumes
[0120] 1. Image Standardization: All membrane micrographs were converted to 8-bit grayscale and inverted to ensure pixel intensity values directly correlated with stain density.
[0121] 2. Constant region of interest (ROI) Analysis: A fixed ROI with a standardized area of 0.313 units was applied across all samples to ensure spatial consistency in measurements.
[0122] 3. Internal Background Subtraction: To account for variations in membrane reflectance or imaging conditions, a background mean intensity was measured for each individual image and subtracted from the stain mean to calculate the corrected mean intensity.4. Comparative Baseline Control: Each formaldehyde concentration set (F0.2 to F5) was analyzed against a specific standard (STD) baseline, allowing for the quantification of intensity changes relative to a baseline for that specific concentration.
[0123] 5. Quantitative Trend Assessment: Data were aggregated into a grouped analysis to evaluate the concentration-dependent response of purpald® (4-amino-3-hydrazino-5-mercapto-1 ,2,4-triazole) and hydrogen peroxide (H2O2) treatments across the formaldehyde gradient.
[0124] Machine learning model
[0125] A machine learning algorithm is used as a guide to develop Al-based learning models to differentiate the control, non-metastatic, and metastatic lung-cancer samples. Continuous data collection from these samples are used to train the models. Skin temperature, humidity, and impedance measurements per hour are the input parameters for the model.
[0126] Statistical Analyses
[0127] All statistical tests are performed in Origin Pro. Pearson's correlation and Bland-Altman analysis performed to determine the extent of agreement of sweat sensor with the reference method. The data confirmed through mean ± S.E. A minimum of n > 5 measurements performed for the calibration experiments.
[0128] EXAMPLE 2
[0129] Biochemistry of volatile organic compounds as metabolic byproducts of Jak3-STAT3 signaling Table 1 shows that VOCs in lung cancer cells are significantly different (p<0.05) than other cancer cells and normal control lung cells. Moreover, the levels of these VOCs are significantly higher than the non-cancerous cells, indicating that the lung cancer cells are the direct sources of these volatile organic compounds, such as hexanal, octanal, nonanal, decanal.
[0130] TABLE 1
[0131] Average of VOCs and Jak3 expression levels in different cells
[0132] Jak3 VOCs
[0133] Cell Cell
[0134] over Hexanal Octanal Nonanal Decanal Heneicosane line type
[0135] express
[0136] A549 lung +++++ ++++++ ++++++ ++++ + + + ++++
[0137] cancer
[0138] Calu lung +++++ ++++ + + + + + + + + + ++++
[0139]
[0140] cancerHela cervical — — — — — — cancer
[0141] NHBE normal + / - + + + + — — —
[0142]
[0143] cells
[0144] FIG. 1 illustrates how detecting the volatile organic compound in the sweat by the skinpatch cannot only mechanistically diagnose non-invasively the early stage from the metastatic stage of lung cancer but also predict the presence of a overexpressed drug target in lung cancer for potential therapeutic monitoring. Drug targets such as Jak3 and STAT3 drive volatile organic compound formation through various ways in cancer cells as follows:
[0145] In the lipid peroxidation pathway constant STAT3 activation by Jak3 leads to increases in aerobic glycolysis and mitochondrial ETC rewiring which leads to ROS accumulation overwhelming antioxidant defenses like SOD2 / GPX4, some ROS leaks persist only in the cancer cells. ROS drives the peroxidation of polyunsaturated fatty acids (PUFAs) in cancer cell membranes leading to the formation of n-aldehydes such as malondialdehyde (MDA), 4-hydroxy-2-nonenal (4-HNE), hexanal, and various other aldehyde volatile organic compounds. These aldehydes are volatile and diffuse into breath and sweat through tumor microenvironment.
[0146] During amino acid catabolism STAT3 reprograms glutamine / serine metabolism where imbalance in these pathways generate reactive aldehydes, formaldehyde and acetaldehyde, during deamination or one-carbon flux. In normal cells STAT3 upregulates ALDH family enzymes (especially ALDH1 / 3), which normally detoxify aldehydes. However, once overwhelmed by a detoxification imbalance, as seen in lung cancer, these aldehyde intermediates accumulate and appear as VOCs that is dateable by the skin-patch.
[0147] GC-MS studies detected elevated VOC aldehydes (hexanal, octanal, nonanal, decanal) in lung cancer, breast, and colorectal cancer patients. These VOCs correlate with inflammation and overexpression in Jak3-STAT3-driven tumors such as lung cancer, though causality is indirect, i.e., Jak3 -^STAT3 — > inflammation / ROS — > lipid aldehydes.
[0148] Together these show that constant STAT3 activation by overexpressed Jak3 contributes to a range of volatile organic compounds in the form of varied molecular weights of several aldehydes. These are formed, mainly via ROS-driven lipid peroxidation of membranes, altered amino acid metabolism and Incomplete aldehyde detoxification.EXAMPLE 3
[0149] Sweat Sensor
[0150] FIG. 2 shows the schematic design for sweat-test device. The sweat-test device is a wearable / skin patch with a sensor device has a sensor membrane and the colorimetric pad reader. The sensor membrane is immobilized with quaternary ammonium aminooxy reagent / metalloporphyrins (ATM) reagents for chemo-selective capture of the VOCs compounds in the sweat of lung cancer patients and is connected to the colorimetric reader membrane layer. This entire wearable skin patch is adherable to the skin, such as placeable on the hand such that the VOC capture membrane interfaces firmly with the skin through selectively permeable membrane barrier that absorbs low volumes of passive sweat from the skin. The volatile organic compounds from diffused sweat are captured by interface membrane that develops color upon adding the color development reagents followed by color stabilizing reagents and the corresponding colorimetric signal are to be measured to obtain the digital values of the signal. Color developed by measuring the colorimetric response from physiological sweat control, and metastatic lung cancer patients are compared with varying concentrations of the standard target analyte.
[0151] FIG. 3 shows the placement of the patch on the skin and identifies the plurality of layers comprising the skin patch. From the top, the patch has a microporous sweat-permeable layer, a reagent coated capture layer, a signal transduction layer, an absorbent layer, and an adhesive backing to removably adhere to the skin.
[0152] EXAMPLE 4
[0153] Detection and analysis of standard aldehyde samples by the skin patch
[0154] Table 1 shows the lung cancer linked aldehydes standards dissolved in artificial physiological sweats that were successfully tested using physiological sweats alone as control. Following standardization, the actual lung cancer patient sweats were tested by the skin-patch. The extracted and aliquoted samples were tested on the sweat sensor for doubleblind validation of volatile organic compounds detection in the sweat. The functionalized skinpatch is scanned through a portable reader to obtain peaks patterns and digitized numeric values for color intensities. The measured peak patterns and the numerical responses are used to differentiate control, non-lung cancer, and metastatic lung-cancer samples. Pearson's correlation is to be performed between the sweat sensor and mass spectrometry data to compare the results from both methods.
[0155] Using the skin-patch, it was first tested to see if it works with all the pure standard biomarkers (FIGS. 4A-4P). For each of the biomarkers, a volume range from 2-1 OpL wastested for color development (Y / N), minimum sweat / standard volume required for detection, and the numerical values of the intensities of the developed color for each of the concentration tested. For sweat detection, as the volume of the fluid can be a limitation, the volume range was first optimized over a range from 0.02pL-5pL for each of the acetaldehyde, formaldehyde, hexanal, octanal, nonanal, hydroxynonana, and decanal aldehyde standards as per the methodology in Example 1 (FIGS. 5A-5G).
[0156] Representative images as an example for standard biomarker-1 in FIGS. 6A-6B shows that with the volume range of about 0.02pL-5pL calibration, Std-1 was detectable using the skin-patch. Similarly, with a total of 8 standard purified forms of the biomarkers in 60 different combinations, the skin patch detected two biomarkers in a volume range of about 0.02-5.0 pL, while five biomarkers of the standards were detectable in a volume range of about 0.2-5.0 pL, while one-biomarker was not detectable.
[0157] Since the skin patch was able to detect 7 out of 8 biomarkers discovered as originating from lung cancer cells using human sweat from confirmed lung cancer patients the skin patch was tested for detection of lung cancer positivity. Table 2 lists the tested samples where each of the standard artificial sweat with or without aldehyde standards or the actual lung cancer patient sweat samples were tested in a volume range from 1-10 pL.TABLE 2
[0158] Physiological sweat and aldehyde standards detection by skin patch
[0159]
[0160] CA: Cellulose Acetate membrane coated with PEI; PTFE: CA membrane coated with PTFE
[0161] Skin patch detection of lung cancer
[0162] Jak3 (Janus Kinase 3; a non-receptor tyrosine kinase) is frequently overexpressed in lung cancer cells compared to other types of cancer (FIG. 7) and known for promoting metastasis of lung-cancer cells where data suggest that these cells also produce VOC (Table 1 ) which differentiates them from non-metastatic normal cells and some other types of cancer. Moreover, staining of lung cancer biopsies shows stages of lung cancer where Jak3 is overexpressed.
[0163] FIGS. 8A-8M illustrates worse first-progression survival (FP) in lung cancer by measuring the probability over time of low and high expression in STAT2, STAT3, STAT4, STAT5A, STAT5B, STAT6, JAK1, JAK2, JAK3, TYK2, SRC, and FYN, respectively. High expression of STAT2, JAK3, and TYK2 correlates with worse FP. Low expression of JAC, JAK2, and FYN correlate with worse FP. FYN has the most significant correlation with overallsurvival (OS) with the lowest hazard ratio (HR) and P values. JAK3-specific overexpression and not JAK1 or JAK2 correlates with worse first progression survival.
[0164] Lung cancer cells have significantly increased production of specific volatile organic compounds in the sweats of early and metastatic lung cancer patient-1 and patient-2 as detected by the skin patch and dip-strip membrane (FIGS. 9C-9F and 8G-8J, respectively) that are different and distinguishable from the VOCs profile in the normal sweats (FIGS. 9A-9B). This demonstrates that the skin patch did not develop any color using control samples while incubation of the skin patch with the sweat samples from the two lung cancer patients produced a distinct and detectable color and corresponding intensity patterns which were differentiated from the control.
[0165] References:
[0166] 1. Bonney et al., Cochrane Database Syst Rev. 2022; 8(8):CD013829, 2022.
[0167] 2. Alicea-Velazquez et al., Curr Drug Targets. 2011 ;12(4):546-55, 2011.
[0168] 3. Kumar eta / ., Mediators Inflamm. 2021 :6618924ID, 2021.
Claims
WHAT IS CLAIMED IS:
1. A device to collect a bodily fluid from a subject as a diagnostic of a lung cancer, comprising:a sensor strip; andmeans to immobilize the sensor strip within the device.
2. The device of claim 1, said sensor strip comprising a plurality of layers configured to chemically select and colorimetrically identify volatile organic compounds present in the bodily fluid.
3. The device of claim 2, wherein the volatile organic compound is an aldehyde.
4. The device of claim 2, said plurality of layers comprising:an absorbent layer selective for the bodily fluid;a signal transduction layer configured to convert a volatile organic compound detected in the bodily fluid into a perceivable color change;a reagent coated capture layer configured to capture the volatile organic compound; anda microporous sweat-permeable layer.
5. The device of claim 4, said plurality of layers further comprising an adhesive layer to secure the device to the subject.
6. The device of claim 1, wherein the means to immobilize the sensor strip is a coated microfiber or a coated membrane in a microchip, said microchip in electronic connection with a colorimetric reader.
7. The device of claim 6, wherein the coated microfiber or the coated membrane comprises a coating of quaternary ammonium aminooxy reagent / metalloporphyrins, polyethyleneimine or 2,4-dinitrophenylhydrasine or a combination thereof.
8. The device of claim 6, wherein the coated microfiber or the coated membrane comprises cellulose acetate membrane ora polytetrafluoroethylene membrane.
9. The device of claim 1, wherein the device is a wearable patch removably attachable to the skin.
10. The device of claim 9, wherein the bodily fluid is sweat.
11. The device of claim 1 , wherein the device is a dip-strip.
12. The device of claim 11 , wherein the bodily fluid is urine or serum.
13. The device of claim 1 , wherein the lung cancer is a metastatic lung cancer.
14. A kit to detect a lung cancer in a subject, comprising:the sensor strip of claim 1 ; anda colorimetric reader in electronic contact with the sensor strip.
15. A method for detecting volatile organic compounds in sweat from a subject in need thereof, comprising:placing a patch comprising the sensor strip of claim 12 on the subject such that the sensor strip interfaces with the skin;absorbing therein passive sweat from the subject;capturing the volatile organic compounds by the coated microfiber or the coated membrane; andmeasuring a colorimetric signal with the colorimetric reader, said signal correlating to a presence of the volatile organic compounds in the sweat.
16. The method of claim 15, wherein the volatile organic compounds are biomarkers for a metastatic lung cancer.
17. The method of claim 15, further comprising diagnosing a lung cancer in the subject as a metastatic lung cancer based on the presence of the volatile organic compounds.
18. A method for treating a metastatic lung cancer in a subject, comprising: administering to the subject a therapeutically effective amount of a Janus Kinase 3-targeted drug.
19. A system to detect aldehydes in passive sweat as biomarkers of a lung cancer in a subject, comprising:a wearable patch with a sensor strip that is a coated microfiber or a coated membrane immobilized in a microchip; anda colorimetric reader in electronic connection with the microchip.
20. The system of claim 19, wherein the coated microfiber or the coated membrane comprises a quaternary ammonium aminooxy reagent / metalloporphyrins, polyethyleneimine or 2,4-dinitrophenylhydrasine or a combination thereof.
21. The system of claim 20, wherein the coated microfiber or the coated membrane are made of cellulose acetate or polytetrafluoroethylene.
21. The system of claim 20, wherein the coated microfiber or the coated membrane comprises:an adhesive layer to interface with the skin;an absorbent layer selective for the passive sweat;a signal transduction layer configured to convert the aldehyde detected in the passive sweat into a perceivable color change;a reagent coated capture layer configured to capture the aldehyde; anda microporous sweat-permeable layer.
22. The system of claim 19, wherein the lung cancer is a metastatic lung cancer.
